References
- Ferlay, J, Bray, F, Pisani, P, Parkin, DM. Globocan 2000. Cancer incidence, mortality and prevalence worldwide. Lyon: IARC Press; 2001.
- Coleman MP, Gatta G, Verdecchia A, Estève J, Sant M, Storm H, et al. EUROCARE-3 summary: Cancer survival in Europe at the end of the 20th century. Ann Oncol 2003; 14(Suppl 5)V128–49
- Berrino F. The EUROCARE Study: Strength, limitation and perspectives of population-based, comparative survival studies. Ann Oncol 2003; 14(Suppl 5)V9–13
- Miller DC, Gruber SB, Hollenbeck BK, Montie JE, Wei JT. Incidence of initial local therapy among men with lower-risk prostate cancer in the United States. J Natl Cancer Inst 2006; 98: 1134–41
- World Health Organisation. International classification of diseases, 9th edition. Geneva: WHO; 1997.
- LH Sobin, Wittekind, CH. TNM classification of malignant tumours, 5th ed. Edited by UICC, International Union against Cancer. New York, Chichester, Weinheim, Brisbane, Singapore, Toronto: Wiley-Liss; 1997.
- Zou G. A modified poisson regression approach to prospective studies with binary data. Am J Epidemiol 2004; 159: 702–6
- Stata Corp. 2001. Stata Statistical Software: Release 9.0. College Station, TX: Stata Corporation.
- Quinn M, Babb P. Patterns and trends in prostate cancer incidence, survival, prevalence and mortality. Part I: International comparisons. BJU Int 2002; 90: 174–84
- Draisma G, Boer R, Otto SJ, van der Cruijsen IW, Damhuis RA, Schröder FH, et al. Lead time and overdetection due to prostate-specific antigen screening: Estimation from the European Randomised Study of screening for prostate cancer. J Natl Cancer Inst 2003; 95: 868–78
- Albertsen PC, Hanley JA, Fine J. 20-year outcomes following conservative management of clinically localized prostate cancer. JAMA 2005; 293: 2095–01
- Johansson JE, Andrén O, Andersson SO, Dickman PW, Holmberg L, Magnuson A, et al. Natural history of early, localized prostate cancer. JAMA 2004; 291: 2713–9
- Aus G, Robinson D, Rosell J, Sandblom G, Varenhorst E. South-East Region Prostate Cancer Group. Survival in prostate carcinoma–outcomes from a prospective, population-based cohort of 8 887 men with up to 15 years of follow-up: Results from three countries in the population-based National Prostate Cancer Registry of Sweden. Cancer 2005; 103: 943–51
- Thompson I, Thrasher JB, Aus G, Burnett AL, Canby-Hagino ED, Cookson MS, et al. Guideline for the management of clinically localized prostate cancer: 2007 update. J Urol 2007; 177: 2106–31
- Graham J, Baker M, Macbeth F, Titshall V. Guideline Development Group. Diagnosis and treatment of prostate cancer: Summary of NICE guidance. BMJ 2008; 336(7644)610–2
- Bill-Axelson A, Holmberg L, Filén F, Ruutu M, Garmo H, Busch C, et al. Radical prostatectomy versus watchful waiting in localized prostate cancer: The Scandinavian prostate cancer group-4 randomized trial. J Natl Cancer Inst 2008; 100: 1144–54